News
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
Your search for tofacitinib returned 21 results
ACR 2019, News
Few Serious Infections in Offspring Exposed to Non-TNFi Biologics, Tofacitinib
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
ACR/ARHP 2018 Annual Meeting
CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
ACR/ARHP 2018 Annual Meeting
Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
ACR/ARHP 2018 Annual Meeting
RA Remission Compared for Tofacitinib Alone vs. Steroid Plus Tofacitinib Tx
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP 2018 Annual Meeting
Obesity Negatively Affects Treatment Response to JAK Inhibitors in RA
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
ACR/ARHP 2018 Annual Meeting
Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
News
FDA Panel Recommends Approval of Tofacitinib for Psoriatic Arthritis
The supplemental New Drug Applications (sNDAs) contained data from Phase 3 trials involving patients with psoriatic arthritis, including safety analyses from the larger tofacitinib clinical development program.
EULAR 2017
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
News
Tofacitinib Goes Head-to-Head with Adalimumab in RA Study
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.
